The Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium will enroll patients with sporadic and familial forms of amyotrophic lateral sclerosis, frontotemporal dementia (FTD), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), and progressive muscular atrophy (PMA). The goals of the CReATe consortium are to advance therapeutic development for this group of neurodegenerative disorders through study of the relationship between clinical phenotype and underlying genotype, and also through the discovery and development of biomarkers.
CReATe Biomarker Pilot Project Request for Applications 2021
The CReATe Consortium in partnership with the ALS Association, is pleased to announce this request for applications (RFA) to support the discovery and/or validation of biomarkers for ALS or a related disorder (including PLS, HSP, PMA, MSP, and FTD).
Deadline to submit the Letter of Intent is May 7, 2021.
For further details click here.